Indian Immunologicals Limited (IIL), a one health company and one of the largest producers of vaccines in Asia, will invest about Rs 700 crore to set up a new animal vaccine manufacturing facility in Genome Valley, Hyderabad, the “Vaccine Hub of the World”, to meet the vaccine security of the nation against economically important diseases such as foot and mouth disease (FMD) and other emerging diseases. The facility will create total employment for around 750 people.
IIL, a subsidiary National Dairy Development Board (NDDB) is already one of the largest manufacturers of FMD vaccine in the world and is the leading supplier of FMD vaccine to the Government of India’s National Animal Disease Control Programme (NADCP). IIL is investing in a new greenfield project for the establishment of a veterinary vaccine facility for manufacturing of foot and mouth disease (FMD) vaccine and other animal vaccines. The facility is intended to be a state-of-art fully integrated biosafety level 3 (BSL-3) for drug substance (DS) production and respective fill-finish.
IIL’s intended new facility, in Genome Valley Phase 3, will add another 300 million doses/annum of FMD vaccine to its capacity. The existing facility in Gachibowli already has a capacity of 300 million doses. Production is scheduled to commence in the 3rd year. IIL is a one health company and the market leader in veterinary and human biologicals in India. It manufactures over 150+ products.
All of these activities will be located in Genome Valley, which is India’s first organized cluster for life sciences R&D and clean manufacturing activities, with world-class infrastructure facilities in the form of Industrial/Knowledge Parks, Special Economic Zones (SEZs), multi-tenanted dry and wet laboratories and incubation facilities. It is home to more than 200 companies with a scientific workforce of about 15,000 professionals including presence of the marquee global names like Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, Lonza amongst many others including other vaccines manufacturers like Bharat Biotech, Biological E, etc.
Dr. K. Anand Kumar, managing director, IIL mentioned, “IIL is on an aggressive growth path and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines and thereby saving the exchequer and farmers several thousands of crores.”
